Overall, considering overexpression of both β-catenin and RAS especially mutant KRAS and their roles in the critical events of the tumorigenesis, inhibition of the Wnt/β-catenin and RAS-ERK signaling especially by destabilization of both β-catenin and RAS could be an ideal therapeutic strategy for treating CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.